Crossmark

Crizotinib Versus Conventional Chemotherapy in First-Line Treatment for ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis

Crossref DOI link: https://doi.org/10.1007/s40487-021-00155-3

Published Online: 2021-06-11

Published Print: 2021-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Cruz, Barbara D. https://orcid.org/0000-0002-4106-7768
Barbosa, Mariana M. https://orcid.org/0000-0003-1465-9167
Torres, Lucas L. https://orcid.org/0000-0002-7770-4597
Azevedo, Pamela S. https://orcid.org/0000-0002-1947-6290
Silva, Vânia E. A. https://orcid.org/0000-0002-0345-8522
Godman, Brian

Alvares-Teodoro, Juliana https://orcid.org/0000-0002-0210-0721
License Information

Text and Data Mining valid from 2021-06-11

Version of Record valid from 2021-06-11
More Information

Article History

Received: 25 February 2021

Accepted: 19 May 2021

First Online: 11 June 2021